The Impact of Trehalose Dimycolate on the Clinical Course of Mycobacterium avium Complex Pulmonary Disease.

Abstract

Rationale The clinical implications of trehalose 6,6'-dimycolate (TDM) in nontuberculous mycobacterial pulmonary disease have not been studied. Objective To examine the presence of TDM in clinical isolates obtained from patients with Mycobacterium avium complex (MAC) pulmonary disease (PD) and its impact on disease severity and treatment outcomes. Methods We analyzed clinical isolates from patients diagnosed with MAC-PD at Seoul National University Hospital between January 1, 2019, and December 31, 2021. The lipids were extracted from clinical isolates obtained at the time of diagnosis using mass spectrometry. Mass peaks between 300 and 3,500 m/z were obtained, and the peak patterns of the total lipids were analyzed. Results TDMs were identified in clinical isolates from 176 out of 343 patients. Cavities were more prevalent in patients with TDM-negative isolates (19.8%) than in patients with TDM-positive isolates (10.2%) (P=0.015). The time to antibiotic treatment was shorter in patients with TDM-negative isolates (4 months, interquartile range [IQR] 2-10) than in patients with TDM-positive isolates (7 months, IQR 3-16, P=0.032). Patients with TDM-negative isolates had a significantly lower proportion of culture conversions (P=0.012). TDM was associated with higher likelihood of culture conversion (adjusted hazard ratio, 2.29; P=0.035). Conclusions TDM-negative isolates were linked to a higher occurrence of cavities, earlier initiation of treatment, and worse treatment outcome in MAC-PD patients.